The latter is highly significant since future vaccines will need to be effective against these relatively resistant early founder strains before infection is established in vivo [50] .
← all excerpts
Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.
1
—
—